Request Demo
Last update 14 Aug 2025
Drotaverine Hydrochloride
Last update 14 Aug 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Drotaverin, Drotaverine, Deolin + [1] |
Target |
Action inhibitors |
Mechanism PDE4 inhibitors(Phosphodieterase 4 inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC24H32ClNO4 |
InChIKeyJBFLYOLJRKJYNV-UHFFFAOYSA-N |
CAS Registry985-12-6 |
Related
21
Clinical Trials associated with Drotaverine HydrochlorideCTRI/2024/11/077285
A prospective, randomized, investigator initiated, assessor blinded, active controlled, single centre, phase IV clinical trial to compare the efficacy and safety of two different formulations of drotaverine in patients with spasmodic pain. - NIL
PACTR202311852717227
Efficacy of drotaverine hydrochloride in reducing duration of labour in term pregnancies at NAUTH, Nnewi: a double-blind randomised controlled study
CTR20233743
盐酸屈他维林片（40mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of drotaverine hydrochloride tablets (40 mg) in Chinese healthy subjects under fasting and fed conditions
100 Clinical Results associated with Drotaverine Hydrochloride
Login to view more data
100 Translational Medicine associated with Drotaverine Hydrochloride
Login to view more data
100 Patents (Medical) associated with Drotaverine Hydrochloride
Login to view more data
300
Literatures (Medical) associated with Drotaverine Hydrochloride05 May 2025Urologiia (Moscow, Russia : 1999)
Results of treatment of acute uncomplicated cystitis in 440 women of working age in a large industrial city
Article
Author: Davidov M, I ; Zaitsev A, V
INTRODUCTION:
Lower urinary tract infections (UTIs) affect nearly two-thirds of all women during their lifetime, and many suffer from recurrent infections. There are evidence-based guidelines from several international societies and RSU for the evaluation and treatment of UTIs; however, adherence to these guidelines is not always optimal.
AIM:
To study the immediate outcomes of treating acute uncomplicated cystitis in working-age women living in a large industrial city under unfavorable environmental and climatic conditions.
MATERIALS AND METHODS:
A multicenter, randomized, open-label study was carried out in 4 outpatient clinics in Perm involving 440 women with acute uncomplicated cystitis. Depending on the treatment, the patients were divided into 4 groups. The main drug was the antibiotic fosfomycin trometamol, which was given at a single dose of 3 g to all 440 patients. In the group 1, monotherapy with fosfomycin trometamol was used. Patients in groups 2-4 received basic antibacterial therapy (3 g of fosfomycin trometamol), supplemented with symptomatic and herbal remedies. In the group 2, drotaverine was used at 80 mg 3 times a day for 2 days, in the group 3 phenazopyridine at a dose of 200 mg 3 times a day for 2 days was given, while in the group 4, Canephron N at 2 tablets 3 times a day for 6 days was administered. The symptoms of cystitis were assessed using the ACSS scale, visual analog scale (VAS) of pain, urinalysis with microscopic examination of urinary sediment, bacteriological examination of urine and other methods. The results were assessed after 6, 12, 24, 48 hours, 3 and 6 days.
RESULTS:
The sensitivity of microorganisms to fosfomycin in bacteriological studies was 97.2%. In group 1, recovery was achieved in 92.5%, improvement in 6.6%, and the bacteriological cure was 95.3%; however, the ACSS and VAS scales indicated insufficiently rapid elimination of pain and other symptoms. In the group 2, improvement in results was insignificant. However, results were significantly better in groups 3 and 4, with rapid resolution of pain, dysuria, and other symptoms. In group 3, recovery was achieved in 97.3%, bacteriological cure and disability period were 96.8% and 5.1+/-0.5 days, respectively. In group 4, recovery was observed in 96.4%, bacteriological cure was 96.6%, and disability period was 5.2+/-0.4 days, respectively. In total, for 440 patients, when using fosfomycin trometamol, recovery occurred in 95.2%, improvement in 4.6%, bacteriological cure was 96.4%, side effects of fosfomycin trometamol were noted only in 1.1% of cases.
CONCLUSIONS:
Currently, even in unfavorable environmental and climatic conditions, fosfomycin trometamol remains a highly effective and safe antibacterial agent for the treatment of acute uncomplicated cystitis. It is recommended to combine the use of fosfomycin trometamol with a urinary analgetic drug and herbal preparation based on extracts of centaury, lovage and rosemary (Kanefron N).
01 May 2025CONTRACEPTION
Smooth muscle relaxants for intrauterine device placement: A systematic review
Review
Author: Snyder, Emily M ; Nguyen, Antoinette T ; Curtis, Kathryn M ; Zapata, Lauren B ; Krishna, Gopika ; Whiteman, Maura K
OBJECTIVES:
To systematically review evidence on whether medications with smooth muscle relaxant properties improve patient and provider outcomes for intrauterine device (IUD) placement.
STUDY DESIGN:
We searched multiple databases through August 2022 for randomized clinical trials assessing smooth muscle relaxants for IUD placement. Primary outcomes were pain experienced with IUD placement, provider ease of placement, need for adjunctive placement measures, placement success, patient satisfaction with procedure, medication side effects occurring before clinic discharge, and adverse events occurring before clinic discharge. We extracted data from included articles, assessed risk of bias for each trial, narratively summarized results, and determined certainty of evidence for all outcomes.
RESULTS:
Five placebo-controlled trials met inclusion criteria; four trials had low risk of bias and one had moderate risk. Two trials of topical nitroprusside gel or nitroglycerin ointment found no differences in patient pain, provider ease of placement, patient satisfaction, placement success, side effects, or adverse events. One trial suggested that drotaverine plus mefenamic acid reduced patient pain but did not improve placement success. Two trials suggested that isonicotinic acid hydrazide reduced patient pain, improved provider ease of placement and patient satisfaction, reduced need for analgesia and for cervical dilation (in one trial) and did not increase side effects; neither trial reported improved placement success.
CONCLUSIONS:
Evidence on smooth muscle relaxants for IUD placement remains sparse with inconsistent findings across specific medications. Certainty of evidence for all outcomes was low for topical nitroprusside gel and nitroglycerin ointment, very low for drotaverine plus mefenamic acid, and mostly high for isonicotinic acid hydrazide.
IMPLICATIONS:
Before IUD placement, healthcare providers can counsel patients on the potential for pain during placement and options for pain management. However, more evidence is needed on specific smooth muscle relaxants to determine their effectiveness as an intervention for IUD placement.
01 Apr 2025JOURNAL OF PHARMACEUTICAL SCIENCES
Optimization of HPLC method for determination of Abraham solvation parameters of pharmaceuticals
Article
Author: Knašienė, Birutė ; Sadaunykas, Audrius ; Sazonovas, Andrius ; Naujalis, Evaldas ; Lanevskij, Kiril ; Balčiūnas, Simonas
Abraham solvation equation (Absolv) is a popular and well-established approach for modeling solute partitioning between phases of different polarity, which finds its applications in both organic chemistry and biomedical fields. Parameters constituting this equation are good quantitative descriptors of solute hydrogen bonding potential that are useful for QSAR modeling of more complex chemical and biological phenomena. Numerous studies dealing with fast determination of Abraham descriptors using HPLC can be found in the literature, but these mostly focus on small un-ionizable industrial and environmental chemicals, whereas experimental data for pharmaceutical molecules are clearly lacking. In the current study we build upon a previously published chromatographic approach, aiming to adapt the method to ionizable drug-like compounds, and optimize it by reducing the number of required HPLC columns. The analysis involves determination of the overall H-bond acidity (A), H-bond basicity (B) and polarity/polarizability (S) descriptors for 62 pharmaceutical molecules with previously unpublished parameter values.
1
News (Medical) associated with Drotaverine Hydrochloride
100 Deals associated with Drotaverine Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Drotaverine Hydrochloride |
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Muscle Spasticity | China | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 650 | (Experimental) | oyygngvbhr(nkqcivpvph) = skdklgcedf csbrwlskxc (dvhwndxmba, 0.89) View more | - | 23 Dec 2009 | ||
(Active Comparator) | oyygngvbhr(nkqcivpvph) = cqlwtvhlyn csbrwlskxc (dvhwndxmba, 0.82) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free